PERTH, Australia – As Australia gets ready for its national election on May 18, the life sciences industry is putting pressure on both political parties to reform the country's research and development tax incentive (RDTI). Read More
Researchers at Pisa's Scuola Superiore Sant'Anna and King's College London have shown that therapeutic administration of miR-199 stimulated cardiac repair in pigs after experimentally induced heart attacks. Read More
Intercept Pharmaceuticals Inc., of New York, said it priced its public offering of 2.4 million shares of common stock at $83.50 per share, for gross proceeds of about $200.4 million. Read More
Verastem Oncology Inc., of Boston, reported $1.7 million in net product revenue from cancer drug Copiktra (duvelisib) in the second full quarter of the product's launch. Read More
Olix Pharmaceuticals Inc., of Suwon, South Korea, expanded its ocular disease pipeline, adding OLX-304A to develop an RNAi therapeutic with a novel target (undisclosed) for treatment of retinitis pigmentosa (RP). Read More
SHANGHAI – When investors started pouring capital into Chinese biotechs like Hua Medicine Ltd., Innovent Biologics Inc. or Cstone Pharmaceuticals Co. Ltd., it was reasonable to wonder what exits they were planning. For a long time, China's major stock exchanges only allowed revenue-generating firms to list, making Nasdaq often the best bet, if not an ideal solution for Chinese biotechs. Read More
WASHINGTON – Scott Gottlieb has been out of the U.S. FDA commissioner's seat for just over one month. Now, he is providing a few of his thoughts on reimbursement and the potential for Medicare for All, which he says has a "seductive political appeal for its seeming simplicity." Read More
PERTH, Australia – Australian regenerative medicine company Orthocell Ltd. saw its stock shoot up 350% on Australia's Securities Exchange (ASX:OCC) last week following interim results of its nerve regeneration trial that saw patients regain sensation and muscle function following Celgro nerve regeneration treatment. Read More
Although some on Wall Street kept faith that the hobbled shares of Fibrogen Inc. will make up their losses as investors pick through the data, pundits meanwhile sought to unriddle the pooled phase III findings offered from the global program with roxadustat, an inhibitor of hypoxia-inducible-factor (HIF) prolyl hydroxylase activity. Read More
Although many public biopharmaceutical companies have struggled to find traction this year, those that are concentrating on developing therapies to treat neurological diseases have performed very well. As a result, by the end of April, the BioWorld Neurological Diseases index, a price-weighted index of representative companies that are developing therapies for CNS diseases, had climbed more than 17% compared to a 14% rise in the Dow Jones Industrial Average. Read More
